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ABSTRACT 
 
Delayed graft function (DGF) is a transplant complication which means a need to dialysis 
throughout the first week after transplantation. This study aimed to ascertain the relationship 
between the two immunomodulatory factors of soluble fms-like tyrosine kinase-1 (sFlt-1) 
and soluble fibrinogen-like protein 2 (sFGL-2) with DGF after transplantation. 
This case-control study was done in 2 groups of 58 kidney transplant patients with and 
without DGF. The control group included the patients who didn’t show DGF symptoms. 
Then, serum levels of sFlt-1and sFGL-2 in all blood samples were measured by ELISA.  
Serum sFlt-1 and sFGL-2 levels were significantly higher in the DGF group compared to 
those in the control group (p≤0.001). sFlt-1 and sFGL-2 serum levels significantly affect 
DGF (p<0.001) in such a way that they may be diagnostic factors of DGF. 
This study showed a significant relationship between sFlt-1 as well as sFGL-2 and DGF. 
Therefore, plasma levels of sFlt-1 and sFGL-2 may be used as diagnostic tools to determine 
the risk of DGF. 
 
Keywords: Delayed graft function; Kidney transplantation; Soluble VEGF receptor-1; 
Soluble fibrinogen-like protein 2 
 
INTRODUCTION 
 
Human kidney transplantation is the most  
effective treatment of chronic advanced renal failure. 
Although this method relieves patients of many  
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complications of dialysis, it has some complications on 
its own, one of which is Delayed Graft Function 
(DGF)
1
 accelerating 10% rate of rejection. While the 
traditional definition of DGF rests on dialysis 
requirement during the first postoperative week, it has 
been functionally defined as increase of serum 
creatinine at least 10% daily on 3 successive days 
during the first week post-transplantation.
2
 Recent 
studies have proved some relationships between DGF 
and long term complications of transplantation
3
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including decreased graft survival and increased risk of 
graft rejection.
4
 
Vascular endothelial growth factor (VEGF) is an 
important growth factor which is secreted by many 
cells and takes part in angiogenesis.
5
 There are 3 main 
VEGF receptor subgroups which may be membrane-
bound or soluble.
6
 Soluble fms-like tyrosine kinase-1 
(sFlt-1) is a splice variant of VEGF receptor-1
7
 which 
is produced by endothelial cells, monocytes and 
platelets and, as a potent antagonist of VEGF, binds 
and sequesters VEGF. Thus, the effectiveness of VEGF 
would be reduced in the presence of increased levels of 
sFlt-1. Considering the inflammatory effects of VEGF,
8
 
we may assume that sFtl-1 modulates the immune 
responses in some pathologies.
9,10
 
Soluble Fibrinogen-Like protein 2 (sFGL-2), as a 
soluble member of the superfamily of proteins related 
to fibrinogen, is a molecule holding regulatory 
capabilities in the immune system and thereby is 
mainly secreted by regulatory T (Treg) cells including 
CD4
+
CD25
+
FoxP3
+
 and CD8
+
CD45RO
low
 ones.
11,12
 In 
fact, this factor induces the apoptosis of different 
immune cells
13-16
 and in this way, it protects the tissue 
to be damaged
17
 in different pathologies such as 
hepatitis C
18
 and transplantation.
19,20
 Although the 
signaling process of sFGL-2 is still unclear, its relation 
to Mitogen-activated Protein Kinase (MAPK) signaling 
pathway
21
 induces the inhibitory functions of 
Th17/Treg cells in different pathologies such as 
tumors.
22
 
sFlt-1 and sFGL-2 have not been addressed as 
effective factors on the pathologic condition of DGF so 
far. Changed levels of sFlt-1and sFGL-2 in DGF 
patients compared to those in non-DGF patients may 
endorse such effectiveness. If so, modulators of such 
factors may be able to affect DGF fate; and in this way, 
they may accelerate the recovery of kidney function to 
normal state after transplantation. 
 
MATERIALS AND METHODS 
 
Study Population 
This retrospective study was performed on 2 groups 
of 58 first kidney-transplant adults with and without 
DGF at Baqiyatallah hospital, Tehran, during 2016. 
Both groups had a living donor and were matched 
according to age, sex, family relation to the donor, 
panel reactive antibody (PRA), no history of 
transfusion, and the rate of HLA mismatch. Having 
excluded any patient with hyperkalemia, urinary as 
well as cardiovascular disease, and any cause of renal 
dysfunction including surgical complications and renal 
vein or artery thrombosis, we confirmed the diagnosis 
of DGF according to each way of a) need for dialysis in 
the first week after transplantation, b) increasing more 
than or decreasing less than 10% of serum creatinine 
within 3 days’ post-transplant. The control group was 
selected from the patients who underwent a transplant 
and did not show the mentioned DGF criteria at the end 
of the first week. The induction, as well as maintenance 
immunosuppression protocol for all recipients, was 
composed of therapeutic adjusted doses of calcineurin 
inhibitors, mycophenolate mofetil, and steroids along 
with the study. There was no event of cytomegalovirus 
(CMV) and BK infection according to standard criteria, 
urinary and respiratory infections, and biopsy-proven 
acute rejection in both DGF and control groups. The 
study protocol was confirmed by the local ethics 
committee (N. KAUMS:3537(. Written informed 
consent was obtained from all participants. 
 
Measurements 
A serum sample was prepared from all 116 
participants as soon as DGF was diagnosed in the DGF 
group and at the end of the first week in the control 
group. Samples were kept at -20 until analysis. Once 
collected, the samples were sent to laboratory and 
serum levels of sFlt-1 and sFGL-2 were evaluated by 
sandwich ELISA, eBioscience USA, according to kit 
recommendations. 
 
Statistics 
The results were expressed as mean±SD. 
Kolmogorov Simonov test for Normality of the 
quantitative variables was assessed. The groups were 
compared by independent t-test and differences in 
proportions were tested using Chi-square and Fisher's 
exact test. Multiple binary logistic regression analysis 
was used to adjust the effect of probable confounding 
variables. Using ROC and Area under Curve, we tried 
to determine the sensitivity and specificity of sFlt-1 and 
sFGL-2 in the diagnosis of DGF. p<0.05 was 
considered statistically significant. All analyses were 
made by the SPSS package (version 16; Statistical 
Package for the Social Sciences, SPSS Inc., Chicago, 
Illinois, USA). 
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RESULTS 
 
Basic and Clinical Characteristics of the Study 
Groups 
Basic and clinical characteristics of the study 
groups are shown in Table 1. Serum sFlt-1 and sFGL-2 
levels were significantly higher in the DGF group 
compared to those in the control group (p<0.001). 
Serum levels of sFlt-1 and sFGL-2 were 
significantly higher in the DGF group compared to 
control ones according to different demographic and 
clinical parameters (p<0.01) (Table 2). 
 
Evaluating the Effect of Different Variables on DGF 
Using multiple logistic regression model to evaluate 
the effect of different confounding variables of age, 
gender, family relationship between donor and 
recipient, HLA-mismatch, percentage of PRA, type of 
medication, sFlt-1 and sFGL-2 on the presence or 
absence of DGF (as the dependent variable), we 
showed that DGF is affected by sFlt-1 (p=0.003) and 
sFGL-2 (p=0.002) levels. The model illustrated that an 
increase in one year of the recipient's age increases the 
DGF risk as much as 17% (OR=1.17), and one-unit 
increase of GFR decreases the risk of DGF as low as 
0.944 times. The DGF risk also decreases with 
cyclosporine consumption (OR=0.091). It was found 
that each unit of increase in sFGL-2 and sFlt-1 levels 
significantly increases the risk of DGF 1.10 times 
(p=0.002) and 1.045 times (p=0.003), respectively. No 
significant effects of the other factors were found. 
However, our model showed a high power of 
expression (Nagelkerke R Square=0.872) and proper 
goodness of fit (p<0.001). GFR had a significant effect 
on DGF (p=0.015) in a way that any unit increase in 
GFR increased the risk of DGF by 6% (Table 3). 
 
Cut-off Points and Predictive Values 
Using ROC curve and Area under Curve (AUC), we 
determined both sensitivity and specificity of sFlt-1 and 
sFGL-2 in the diagnosis of DGF. Analysis of ROC in 
cut-off point of 64.7 pg/mL for sFlt-1 showed 91.4% 
sensitivity and 74.1% specificity (AUC=0.955). 
Positive predictive value (PPV) and negative predictive 
value (NPV) of the test were 90.5% and 98.1%, 
respectively (Figure 1). 
Analysis of ROC showed 98.3% sensitivity and 
89.7% specificity at the cut-off point of 55.9 for sFGL-
2 in the diagnosis of DGF (AUC=0.966) (Figure 1). 
Positive predictive value (PPV) and negative predictive 
value (NPV) of the test were 90.5% and 98.1%, 
respectively. 
 
 
Table 1. Basic and clinical characteristics of the patients with or without delayed graft function (DGF) 
Scale Variable DGF Without DGF p value 
Demographic 
characteristics 
Age (Mean±SD) 45.5±11.6 45.6±11.7 0.949 
Sex (Male%) 37(63.8%) 27(46.6%) 0.062 
Family relation 44(75.9) 50(86.2) 0.155 
HLA mismatch (Mean±SD) 3.83±0.92 3.53±0.98 0.099 
GFR 48.92±16.13 50.73±18.46 0.575 
Biochemistry 
characteristics 
 
LDL mg/dl (Mean±SD) 131.1±48.6 122.3±45.1 0.317 
ALT IU/L(Mean±SD) 41.8±22.9 40.7±27.9 0.805 
AST IU/L(Mean±SD) 31.1±14.1 32.6±14.3 0.058 
K+  mEq/L (Mean±SD) 4.4±0.42 4.3±0.49 0.394 
Cr mg/dl (Mean±SD) 1.88±1.36 1.66±1.22 0.345 
Cell counts WBC (Mean±SD) 7.38±2.63 8.45±3.5 0.064 
Platelets (Mean±SD) 18.1±6.2 19.6±6.4 0.218 
Hb g/dl (Mean±SD) 12.2±2.39 11.7±1.7 0.192 
sFlt-1pg/mL (Mean±SD) 142.3±52.5 53.1±17.4 <0.001 
sFGL-2 pg/mL (Mean±SD( 80.34 ± 20.25 40.44 ± 14.73 <0.001 
DGF: Delayed Graft Function, HLA: Human Leukocyte Antigen, GFR: Glomerular Filtration Rate, LDL: Low Density Lipoprotein, ALT: Alanine 
Amino Transferase, AST: Aspartate amino Transferase, K+: Potassium, Cr: Creatinine, WBC: White Blood Cells, Hb: Hemoglobin, sFlt-1: soluble 
fms-like tyrosine kinase-1, sFGL-2: soluble Fibrinogen-like protein 2 
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Table 2. Serum levels of sFlt-1 and sFGl-2 according to different variables in patients with or without delayed graft function 
(DGF) 
Variable With DGF 
(Mean±SD( 
Without DGF 
(Mean±SD( 
p value 
Age (year) <40 sFlt-1 141.9±48.7 54.3±16.4 <0.001 
sFGL-2 79.10 ± 20.33 43.29 ± 15.44 <0.001 
≥40 sFlt-1 142.4±55.1 52.2±18.2 <0.001 
sFGL-2 85.58 ± 20.12 38.71 ± 14.23 <0.001 
Sex Male sFlt-1 150.4±53.2 51.4±17.3 <0.001 
sFGL-2 84.11 ± 19.47 39.99 ± 14.87 <0.001 
Female sFlt-1 127.8±49.4 54.5±17.6 <0.001 
sFGL-2 81.99 ± 21.99 40.84 ± 14.85 <0.001 
HLA mismatch <3 mismatches sFlt-1 133.6±43.9 56.4±16.1 <0.001 
sFGL-2 77.96 ± 22.04 49.19 ± 16.35 0.009 
≥3 mismatches sFlt-1 145.2±55.40 50.3±18.2 <0.001 
sFGL-2 84.08 ± 20.12 38.84 ± 14.01 <0.001 
Family relation Yes sFlt-1 134.6±53.2 53.5±18.3 <0.001 
sFGL-2 79.89 ±17.51 39.79 ± 15.04 <0.001 
No sFlt-1 166.4±43.9 50.1±10.8 <0.001 
sFGL-2 94.18 ± 24.85 44.53 ± 12.72 <0.001 
Drugs used Cyclosporine sFlt-1 155.3±49.4 55.3±17.6 <0.001 
sFGL-2 87.81 ± 21.71 40.62 ± 13.95 <0.001 
Tacrolimus sFlt-1 76.6±28.4 44.5±18.8 0.008 
sFGL-2 79.34 ± 20.44 39.86 ± 20.21 0.001 
HLA: Human Leukocyte Antigen, sFlt-1: soluble fms-like tyrosine kinase-1, sFGL-2: soluble Fibrinogen-like protein 2 
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Figure 1. Receiver operating characteristic (ROC) of sFtl-1 and sFGL-2 for diagnosis of delayed graft function (DGF) 
 
H. Akbari, et al. 
416/ Iran J Allergy Asthma Immunol                           Vol. 18, No. 4, August 2019 
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir) 
Table 3. Multiple logistic regression model for evaluating the effect of different variables on delayed graft function (DGF) 
Independent variables Coefficients(B) S.E. of B Sig. Exp(B) 
Age of recipient 0.156 0.071 0.028 1.169 
Cyclosporine consumption -2.399 0.826 0.004 0.091 
GFR 0.057 0.024 0.015 1.059 
sFGL-2 0.100 0.032 0.002 1.105 
sFlt-1 0.044 0.015 0.003 1.045 
GFR: Glomerular Filtration Rate, sFlt-1: soluble fms-like tyrosine kinase-1, sFGL-2: soluble Fibrinogen-like protein 2 
 
DISCUSSION 
 
Our study demonstrated that sFlt-1serum levels are 
associated with DGF after kidney transplant. This result 
is in line with other studies. For example, in a relevant 
study, patients with DGF showed higher plasma levels 
of sFlt-1.
23
 sFlt-1 (as a VEGF receptor) traps VEGF 
which is an angiogenic factor facilitating immune cell 
migration and adhesion; therefore, sFlt-1 may 
negatively regulate the inflammatory condition of graft 
dysfunction in organs like lungs
24
 and kidneys 
experiencing DGF. Such result is confirmed by the 
observation that a recombinant version of natural sFlt-
1
25,26
 as well as its adenovirus- or plasmid-mediated 
gene transfer
27
 may inhibit angiogenesis and 
inflammatory indices. Similarly, antagonizing VEGFR-
2 by a soluble VEGFR-2 recombinant chimeric protein 
ameliorates graft rejection in mice undergoing corneal 
transplant
28
 which is well in line with a predominant 
anti-inflammatory mode of action of this treatment. 
Showing a significant positive correlation between sFlt-
1 and DGF in our patients, we may consider that 
following DGF, sFlt-1 increases likely as a protective 
mechanism ameliorating the disease pathology. This 
might explain the reason that murine collagen-induced 
arthritis could be therapeutically inverted via sFlt-1.
29
  
This study was also designed to examine, for the 
first time, the possible effect of sFGL-2 on DGF. 
sFGL-2 is secreted from Tregs which have regulatory 
capabilities in some pathologic conditions. For 
example, previous studies have shown significantly 
increased serum level of sFGL-2 in allograft kidney 
transplant recipients with acute rejection
30,31
 perhaps 
due to the fact that the host tries to compensate for the 
injury during acute rejection process.
32,33
 Showing a 
significant positive correlation between sFGL-2 and 
DGF in our patients, we may consider that following 
DGF, sFGL-2 increases likely as a protective 
mechanism ameliorating the disease pathology. 
Actually, the emergence of more sFGL-2 in splenic 
Tregs of transplant models indicates the involvement of 
such factor in inhibitory functions of Tregs
34
 as well as 
long-term survival after transplantation.
35
 Although the 
sFGL-2 impact is uncertain on B cells, it may protect 
the graft through apoptosis of such cells.
36
 
Our study suffered from some limitations. First, 
functional assays which provide further information on 
the immunomodulatory effect of sFlt-1, as well as 
sFGL-2 on DGF, were not performed. Second, we 
missed an extra checkpoint sampling. Further control 
points yield a better assessment of such factors in the 
prediction of DGF. 
The results of our study showed an increased serum 
level of sFlt-1 as well as sFGL-2 associated with DGF. 
Considering their inhibitory roles, we may consider a 
protective role for both molecules among DGF. This 
concept may confirm the beneficial effects of sFlt-1 
and sFGL-2 as diagnostic factors as well as novel 
therapeutics in DGF conditions after transplantation. 
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